BioSpace News Archive

Allogene Therapeutics, Inc. announced it will restate previously issued financial statements for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the December 2020 formation of the Allogene Overland Biopharm joint venture in Asia.

Schrödinger, Inc. reported that on February 13, 2024, the company granted non-statutory stock options to purchase 4,800 shares of the company’s common stock to four newly hired employees and restricted stock units with respect to 5,550 shares of the company’s common stock to eight newly hired employees.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a groundbreaking study published in the Journal for ImmunoTherapy of Cancer.

Novartis announced that the US Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Sharps Technology, Inc. is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market.

Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has approved AMTAGVI™ suspension for intravenous infusion.

The U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer that is unable to be removed with surgery or has spread to other parts of the body that previously has been treated with other therapies.

TransMedics Group, Inc. announced that on February 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 4,041 shares of its common stock and an aggregate of 2,627 restricted stock units to 9 employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to four new employees.